Ipsen Acquires Memo Therapeutics for Up to $800 Million

Ipsen has announced its acquisition of Memo Therapeutics in a deal valued at up to $800 million (over €700 million).

1 Jul, 05:24 — 1 Jul, 12:48

Why this matters

This acquisition represents a strategic expansion for Ipsen, a global specialty pharmaceutical group, into new therapeutic areas or technologies offered by Memo Therapeutics. Such deals are crucial for pharmaceutical companies to enhance their pipelines and market presence.

Key entitiesIpsen Memo Therapeutics

The Story

What 2 sources agree on, dispute, and miss

What sources agree on

Ipsen is acquiring Memo Therapeutics
The acquisition is valued at up to $800 million

Key claims2 agreed · 1 unverified

✓

Ipsen will acquire Memo Therapeutics

agreed·Yahooseeking-alpha

✓

The deal is valued at up to $800 million

agreed·Yahooseeking-alpha

The deal is worth over €700 million

unverified·seeking-alpha

The Story

Analyzing sources…

Source Diversity

Moderate (27/100)

2 sources— more sources would strengthen this score15/33

Spectrum spread— 2/5 buckets covered8/33

Far L

Left1

Left (1)

Yahoo

Center

Right1

Right (1)

seeking-alpha

Far R

Geographic diversity— 1 region4/34

US2

ℹAll sources from US region

ℹOnly 2 sources cover this story

Sources

Showing 2 of 2 sources

YahooMostly Factual8h ago